Back
2019
Deal

Arvelle Therapeutics raises USD 180 million in Series A financing

A global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners supported new company Arvelle Therapeutics with a USD 180 million financing to acquire the exclusive rights from Korean SK Biopharmaceuticals to develop and commercialise cenobamate in Europe.

VISCHER advised Arvelle Therapeutics as Swiss Counsel. The VISCHER team included Dr. Adrian Dörig (Partner, Banking & Finance), Seraina Jenny-Tsering (Managing Associate, Banking & Finance), Ruben Masar (Senior Associate, Corporate) and Christoph Niederer (Partner, Tax).

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert

Contact

VISCHER AG, Zürich
Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

VISCHER AG, Basel
Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions